The price touched fair value on 10/23/2026: +42.22% from the DD reference price of $2.25. DD not tracked on social: the outcome is measured from the report reference price, not from a publication date. Thesis played out — this report is a historical document, no longer maintained.
NAUT is an asymmetric platform call rather than a conventional value stock: the balance sheet funds the 2027 launch window, first revenue has arrived, and the September Nature Methods publication improves technical credibility. The offset is equally clear: revenue is still immaterial, the shelf/ATM creates dilution risk, and the recent rally reduced the cash-discount margin of safety.
The primary model is a probability-weighted platform NAV anchored to the 2026-06-30 cash/investment base, not a reverse-engineered revenue multiple. The implied base enterprise value after cash is about $277M, within the broad range of public proteomics/tool platform optionality but still below the $3.83 analyst consensus. A +/-10 percentage point change in platform success probability moves FV by roughly +/-20%, so this is a milestone-sensitive call. Not investment advice.
| Component | Assumption | USD/share |
|---|---|---|
| Cash and investments floor | $129.2M cash/equivalents/investments at 2026-06-30 / 127.26M shares | +1.02 |
| Tau proteoform application | 35% probability x $380M NPV for Tau EAP to mid-2027 kit pathway / 127.26M shares | +1.04 |
| AKT1 and oncology assays | 25% probability x $350M NPV for AKT1 plus second oncology assay / 127.26M shares | +0.69 |
| Voyager instrument launch | 25% probability x $300M platform value if early-2027 preorders and mid-2027 shipments occur | +0.59 |
| Broadscale consumables option | 15% probability x $250M follow-on reagent/software option / 127.26M shares | +0.29 |
| ATM dilution reserve | 10% potential share-count dilution at $2.25 reference price, before full commercial proof | -0.23 |
| Execution and burn reserve | 40% probability x $65M launch-delay/burn reserve / 127.26M shares | -0.20 |
| FV base case | $1.02 + $1.04 + $0.69 + $0.59 + $0.29 - $0.23 - $0.20 | $3.20 |
Short interest rose 41% between the mid-September and end-September reports, likely reflecting skepticism toward the sudden price move and financing risk. Insider context is mixed: CEO Sujal Patel purchased 25,000 shares in March 2026, while Andreessen Horowitz-affiliated holders reported a 5.0M-share sale at $2.35 in June 2026.
| Item | FY2024 | FY2025 | 1H2026 | FY2026E | Guidance / read-through |
|---|---|---|---|---|---|
| Revenue | $0M | $0M | $0.2M | $0.4M-$1.0M | Early Access and grant revenue only; not yet product revenue |
| Net loss | N/D | -$59.0M | -$29.2M | -$58M to -$65M | Burn remains launch-dependent |
| Cash / investments | N/D | $103.4M | $129.2M | ~$95M-$115M | Before any ATM draw; enough for near-term launch milestones |
| Commercial stage | Development | Pre-EAP | EAP launched | Preorders prep | Instrument shipments expected mid-2027 |
| Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
| Revenue ($M) | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 |
| Gross margin % | N/D | N/D | N/D | N/D | N/D |
| Net loss ($M) | -15.0 | -13.6 | N/D | -14.7 | -14.5 |
| Cash/investments EOP ($M) | N/D | ~168 | 103.4 | N/D | 129.2 |
Business model - single-molecule proteomics platform
Early Access services ~$0.2M Q2 2026; modest near-term revenue proof point Customer samples are run inside Nautilus facilities, generating validation data ahead of consumable-kit general availability. Voyager instruments Preorders expected early 2027 binary launch The instrument launch is the largest value gate. Shipments are expected in mid 2027, but manufacturing and service readiness remain unproven. Targeted proteoform assays Tau available in EAP; AKT1 expected late 2026 ramping Tau validates neuroscience relevance; AKT1 and a second oncology assay expand the platform into oncology use cases. Broadscale consumables General availability targeted after instrument launch option value If adoption emerges, recurring consumables and data workflows can matter more than first instrument gross profit.
Legal, regulatory and risk analysis
SWOT analysis
- +Cash and investments provide runway into the 2027 launch window.
- +Peer-reviewed tau publication supports technical credibility.
- +First revenue and customer engagement create proof points before instrument launch.
- −Revenue is still immaterial and product shipments are not yet underway.
- −Operating losses will continue until platform adoption is visible.
- −Recent rally reduces the original cash-discount setup.
- →AKT1 and oncology assays can broaden customer use cases.
- →Voyager preorders in early 2027 can convert scientific validation into commercial demand.
- →Recurring consumables can create a higher-quality model if installed base grows.
- !ATM issuance can cap upside and dilute existing holders.
- !A launch delay would push valuation back toward cash value.
- !Proteomics-tools peers compete for customer budgets and mindshare.
Summary by assessment area
- Nature Methods publication gives external technical validation.
- Tau, AKT1 and oncology assays create a visible 2026-2027 roadmap.
- Base FV of $3.20 implies about 42% upside from the Oct. 9 close.
- Cash floor reduces downside but no longer fully covers the current market cap.
- Execution timing and dilution are the two most important variables.
- This works only if the 2027 launch path becomes more visible before cash burn erodes the floor.
Sources: Nautilus Q2 2026 earnings release and Q2 2026 Form 10-Q; Nautilus September 2026 Nature Methods / tau proteoform publication materials; SEC September 2026 S-3 and 8-K for the $300M shelf and $125M ATM program; StockAnalysis and MarketBeat quote snapshots; MarketBeat short-interest and analyst-target pages; public insider-trading pages for June 2026 Form 4 activity. Market data as of 2026-10-09 close: NAUT current price used $2.25, market cap ~$286.32M, 52W range $0.82-$4.31, shares outstanding ~127.26M, short interest 5.77M shares / 7.70% of float / 1.4 days to cover as of 2026-09-30. Price sanity check: $2.25 x 127.26M shares ~= $286.34M market cap, consistent with reported market cap. This document is for informational purposes only and does not constitute financial or investment advice.